1. Home
  2. WEAV vs INDP Comparison

WEAV vs INDP Comparison

Compare WEAV & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weave Communications Inc.

WEAV

Weave Communications Inc.

HOLD

Current Price

$7.19

Market Cap

413.7M

Sector

Technology

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.47

Market Cap

350.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEAV
INDP
Founded
2011
2000
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
413.7M
350.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
WEAV
INDP
Price
$7.19
$2.47
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$11.00
N/A
AVG Volume (30 Days)
1.1M
152.2K
Earning Date
04-30-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
7.50
N/A
EPS
N/A
N/A
Revenue
$239,024,000.00
N/A
Revenue This Year
$17.20
N/A
Revenue Next Year
$13.74
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.99
N/A
52 Week Low
$4.24
$0.92
52 Week High
$8.28
$10.91

Technical Indicators

Market Signals
Indicator
WEAV
INDP
Relative Strength Index (RSI) 68.86 44.26
Support Level $6.94 $2.42
Resistance Level $7.31 $3.11
Average True Range (ATR) 0.31 0.22
MACD 0.06 -0.07
Stochastic Oscillator 72.21 11.11

Price Performance

Historical Comparison
WEAV
INDP

About WEAV Weave Communications Inc.

Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and generates revenue mainly from subscriptions.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: